Q Therapeutics 10-Q 2013 Q3 Quarterly report

EXHIBIT 32.1

Q Therapeutics, Inc.

(A Development Stage Company)

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Deborah A. Eppstein, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Form 10-Q of Q Therapeutics, Inc. for the quarter ended September 30, 2013,fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Form 10-Q fairly presents in all material respects, the financial condition and results of operations of, Q Therapeutics, Inc.

Date: November 14, 2013	By:	/s/ DEBORAH A. EPPSTEIN
		Deborah A. Eppstein, PhD
		Chief Executive Officer, President
		(Principal Executive Officer)

I, Steven J. Borst, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Form 10-Q of Q Therapeutics, Inc. for the quarter ended September 30, 2013,fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Form 10-Q fairly presents in all material respects, the financial condition and results of operations of, Q Therapeutics, Inc.

Date: November 14, 2013	By:	/s/ STEVEN J. BORST
		Steven J. Borst
		Chief Financial Officer, VP Corporate Development
		(Principal Financial Officer and Principal Accounting Officer)

* This certification shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.